Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 9/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20576777 | 0.82 | MEN1 (0.49) | MEN1KMT2AIGF1RPIK3C3 | |
| SCHEMBL13081884 | 0.81 | IGF1R (0.50) | MEN1KMT2AIGF1RPIK3C3 | |
| SCHEMBL14722650 | 0.78 | PAK4 (0.59) | AURKAPAK4PAK1IGF1R | |
| SCHEMBL22327874 | 0.75 | PRCP (0.42) | AURKAPAK4PAK1IGF1R | |
| SCHEMBL22535673 | 0.72 | NTRK1 (0.41) | AURKAPAK4PAK1 | |
| SCHEMBL20575194 | 0.69 | MEN1 (0.55) | AURKAPAK4MEN1KMT2AIGF1R | |
| SCHEMBL14722771 | 0.68 | ALDH1A1 (0.36) | AURKAPAK4PAK1IGF1RMKNK1 | |
| SCHEMBL374080 | 0.67 | HCAR3 (0.48) | MEN1KMT2ANPC1 | |
| SCHEMBL27239570 | 0.66 | CCNA2 (0.44) | PAK4PAK1IGF1R | |
| SCHEMBL20449945 | 0.65 | MEN1 (0.68) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738033-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738033-B2 | Trk inhibition | NGF, NGFR, NTRK2 | AURKA 527/4885PAK4 1045/4885PAK1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.